If you have ever searched the words "kratom drug," you have probably noticed something strange. Some sites call kratom a stimulant. Others compare it to opioids. A few label it a supplement, and at least one federal agency wants it scheduled outright. The word "drug" is doing a lot of work in this conversation, and most of the confusion comes from people using it in three completely different ways at once.
This guide pulls those three threads apart. We will walk through how kratom is officially classified in 2026, what its alkaloids actually do at the receptor level, whether it shows up on a drug test, and the real-world drug interactions worth taking seriously. Everything here is sourced from peer-reviewed pharmacology, the FDA's most recent statements, and lab toxicology data, not forum hearsay.
By the end you will know exactly what kratom is, what it isn't, and how to make sense of the next headline that calls it a "dangerous drug" or a "natural alternative."
Table of Contents
- The Three Meanings of "Kratom Drug"
- Is Kratom Officially Classified as a Drug?
- What Drug Class Does Kratom Belong To?
- The Pharmacology: How Kratom Acts on the Body
- Does Kratom Show Up on a Drug Test?
- Kratom Drug Interactions to Know
- Side Effects, Tolerance, and Dependence
- Legal Status Snapshot for 2026
- Frequently Asked Questions
- Final Thoughts
TL;DR
Kratom is not a federally scheduled controlled substance in the United States as of 2026, and the FDA has not approved it as a drug for any medical use. It is a botanical product whose two main alkaloids, mitragynine and 7-hydroxymitragynine, have partial agonist activity at mu-opioid receptors plus stimulant-adjacent effects on adrenergic and serotonergic pathways. Standard 5-panel and 10-panel workplace drug tests do not detect kratom, but specialty kratom panels exist and can return a positive result for up to seven days after the last dose. Always disclose kratom use to a prescribing doctor.
The Three Meanings of "Kratom Drug"
The phrase "kratom drug" gets typed into search bars roughly 39,000 times a month, and people typing it usually want one of three different answers.
The first meaning is regulatory. They want to know whether kratom is illegal, scheduled, or considered a "drug" by federal law the way heroin or even cannabis is. The second meaning is pharmacological. They want to know what category of drug kratom is, similar to asking whether caffeine is a stimulant or a depressant. The third meaning is practical. They are about to take a drug test and want to know whether the kratom in their tea this morning is going to flag a positive.
We are going to answer all three because most articles only answer one and leave the other two muddled. If you skim the headers you can jump to whichever question brought you here.
Is Kratom Officially Classified as a Drug?
In the strictly legal sense, kratom is not a controlled drug at the federal level in the United States in 2026. The Drug Enforcement Administration placed kratom on its "Drugs and Chemicals of Concern" watchlist back in 2016 and briefly proposed scheduling it as a Schedule I substance the same year, which would have put it in the same category as heroin. After significant pushback from researchers, congressional offices, and an estimated 23 million regular users, the DEA withdrew the scheduling proposal and has not reissued it.
The FDA, separately, has consistently warned consumers against using kratom and continues to refuse to recognize any medical use. The agency has issued import alerts, seized shipments, and pursued enforcement actions against companies making unapproved health claims. None of that, however, makes kratom itself illegal at the federal level. It exists in what regulatory analysts call a "gray channel," sold legally as a botanical product with no FDA-approved medical indication.
State-level reality is messier. Six states (Alabama, Arkansas, Indiana, Rhode Island, Vermont, and Wisconsin) ban kratom outright as of early 2026. Several others, including Oregon, Utah, Nevada, Arizona, Georgia, and Colorado, have passed Kratom Consumer Protection Acts (KCPAs) that legalize kratom but require lab testing, age limits, and labeling standards. The patchwork keeps shifting; if you travel or ship product, check your state's most recent statute.
So when someone asks "is kratom a drug?" the cleanest legal answer is: it is a regulated botanical, not a federally scheduled drug, and not an FDA-approved medication. It sits in its own category.
What Drug Class Does Kratom Belong To?
Pharmacologically, kratom is unusual enough that no existing drug class describes it cleanly.
The active compounds are alkaloids extracted from the leaves of Mitragyna speciosa, a tree native to Southeast Asia. The two that matter for effects are mitragynine, which makes up roughly 66 percent of the alkaloid content of typical leaf, and 7-hydroxymitragynine, which is a much smaller fraction (around 2 percent) but binds opioid receptors much more strongly. There are at least 40 other alkaloids present in trace amounts.
Researchers at Columbia University and the University of Florida who have characterized these molecules describe kratom as a "dual-action botanical" with partial mu-opioid agonist activity layered on top of adrenergic and serotonergic effects. In practical terms, low doses (one to four grams of leaf powder) tend to produce stimulant-like effects: alertness, mild euphoria, sociability, sometimes a coffee-like edge. Higher doses (five grams and up) shift toward sedation, pain relief, and a calmer headspace. This biphasic dose response is the single most distinctive feature of the plant and is why it does not fit neatly into "stimulant" or "opioid."
If you forced a categorization, the most accurate phrase is "atypical opioid agonist with stimulant properties at low doses." That is also why kratom shows up in conversations about both ADHD and chronic pain, two patient populations that almost never overlap pharmacologically.
The Pharmacology: How Kratom Acts on the Body
Stepping one layer deeper, here is what is actually happening when an adult drinks a cup of kratom tea.
Mitragynine and 7-hydroxymitragynine bind to mu-opioid receptors as partial agonists, meaning they activate the receptor but produce a weaker maximal response than full agonists like morphine or fentanyl. Crucially, they appear to be biased agonists, preferentially activating G-protein signaling pathways while largely sparing the beta-arrestin pathway. Beta-arrestin signaling is implicated in respiratory depression, which is the mechanism that makes traditional opioids dangerous in overdose. This bias is the leading scientific explanation for why kratom-only fatalities are rare compared to its level of use.
At the same time, mitragynine acts as an antagonist at delta and kappa-opioid receptors, an alpha-2 adrenergic agonist (similar in mechanism to clonidine), and a weak agonist at serotonin 5-HT2A and 5-HT2C receptors. The adrenergic and serotonergic activity drives the stimulant-like profile at low doses, and the partial mu-opioid activity drives the sedation and analgesia at higher doses.
Onset is typically 15 to 30 minutes after oral consumption, with peak effects around 60 to 90 minutes and a total duration of three to six hours. The half-life of mitragynine is around 23 hours, meaning the compound itself stays in the system far longer than the subjective effects would suggest. That long tail matters when we get to drug testing.
| Receptor | Mitragynine activity | Effect contribution |
|---|---|---|
| Mu-opioid (MOR) | Partial agonist (G-protein biased) | Analgesia, sedation, mild euphoria |
| Delta-opioid (DOR) | Antagonist | Limits dysphoria |
| Kappa-opioid (KOR) | Antagonist | Limits dysphoria |
| Alpha-2 adrenergic | Agonist | Anxiolysis, blood pressure modulation |
| Serotonin 5-HT2A/2C | Weak agonist | Mood lift, appetite changes |
| Adenosine A2A | Weak antagonist | Stimulant-like alertness |
Does Kratom Show Up on a Drug Test?
This is the most-searched question in the entire kratom topic, so the answer needs to be specific.
Standard workplace drug testing in the United States looks for a defined set of substances. The federal SAMHSA 5-panel screens for amphetamines, cocaine metabolites, opiates (codeine, morphine, heroin metabolite), phencyclidine, and THC. The expanded 10-panel adds barbiturates, benzodiazepines, methadone, methaqualone, and propoxyphene. Kratom is on neither of these panels. Mitragynine is structurally unrelated to morphine and does not cross-react with the antibodies used in standard immunoassays.
That means the realistic short answer is: kratom does not show up on a normal drug test. There are, however, three important exceptions.
First, specialty kratom-specific panels exist. Quest Diagnostics, Labcorp, and several smaller toxicology labs offer mitragynine assays as add-on tests, typically by liquid chromatography-mass spectrometry (LC-MS/MS). These are usually only ordered by court systems, drug treatment programs, or military testing protocols, not routine pre-employment screens. If your employer specifically wants to test for kratom, they have to ask for it.
Second, there have been documented cases where kratom triggered a false-positive for methadone or PCP on certain immunoassay platforms. The false-positive rate is low but not zero, and confirmatory LC-MS/MS would clear the result.
Third, adulterated kratom products have been reported. A small subset of unregulated extract products and "shots" in 2023 and 2024 were found to contain undisclosed pharmaceuticals like phenibut or low-dose tramadol. If you take an extract product that turns out to contain a real opioid, that opioid will show up on a standard panel, even though kratom itself wouldn't have. This is one of the strongest arguments for buying only from vendors that publish third-party Certificates of Analysis (COAs).
Detection windows on a kratom-specific panel are roughly:
| Sample type | Detection window |
|---|---|
| Urine | 5 to 7 days |
| Blood | 24 hours |
| Saliva | 6 to 24 hours |
| Hair | Up to 90 days |
Heavy daily users will sit at the upper end of these ranges; an occasional user clearing a single dose may test negative within 48 hours.
Kratom Drug Interactions to Know
Because kratom touches opioid, adrenergic, and serotonergic systems, it has a respectable interaction profile that any user should know before combining it with anything else.
The clearest mechanism is hepatic. Mitragynine is primarily metabolized by the cytochrome P450 enzymes CYP3A4 and CYP2D6. Strong inhibitors of those enzymes, including grapefruit juice, certain SSRIs (especially fluoxetine and paroxetine), some HIV antiretrovirals, and ketoconazole, can elevate mitragynine plasma levels and increase the risk of side effects.
Polysubstance combinations carry the most risk. Toxicology data from the CDC analyzed in a 2019 review summarized by the National Institute on Drug Abuse identified that the vast majority of kratom-associated fatalities involved at least one other substance, most commonly fentanyl, benzodiazepines, alcohol, or stimulants. Kratom by itself, in unadulterated leaf form, has been associated with extremely few mono-intoxication deaths. For a deeper dive on toxicity thresholds, see our companion guide on kratom overdose risk.
Practical interaction checklist:
- Do not combine kratom with other opioids. Even partial agonists can stack respiratory depression with full agonists.
- Do not combine kratom with benzodiazepines or alcohol. This is the single most documented risk factor in case reports.
- Use caution with SSRIs and SNRIs. Theoretical serotonin syndrome risk plus CYP-mediated level increases.
- Avoid stacking with stimulants. The cardiovascular load (increased heart rate, blood pressure) compounds.
- Disclose kratom to your prescriber. This is the single most important thing on this list. Doctors cannot work around an interaction they do not know about.
Side Effects, Tolerance, and Dependence
Honest expectations matter. Kratom is not benign, and a guide that pretends otherwise is not useful.
Common short-term side effects, according to Mayo Clinic guidance, include nausea (the most common reason new users abandon kratom), constipation, dry mouth, sweating, dizziness, and itching. Cardiovascular effects can include modest increases in blood pressure and heart rate, particularly with white vein and high-dose stimulant-leaning use.
Tolerance develops with daily use. Most regular users notice that a dose that produced strong effects in week one feels noticeably weaker by week six. This is similar to caffeine tolerance but progresses faster with high-dose extract use than with traditional leaf powder.
Dependence is real and worth taking seriously. Daily users who stop abruptly after several months can experience a withdrawal syndrome that is qualitatively similar to mild opioid withdrawal: restless legs, runny nose, sweating, insomnia, irritability, and gastrointestinal upset. Symptoms typically peak at 48 to 72 hours and resolve within seven to ten days. The intensity is generally rated as much milder than withdrawal from prescription opioids, but it is not nothing, and people who have wrestled with it describe the experience as genuinely uncomfortable. Tapering rather than cold-stopping is the standard recommendation.
The American Kratom Association estimates that around 16 to 18 percent of regular daily users develop a dependence pattern that meets clinical criteria for substance use disorder. That number is meaningful and is one of the reasons the FDA continues to push for stricter regulation.
Legal Status Snapshot for 2026
A quick reference on where kratom stands at the federal and state level entering 2026.
Federal (United States). Not scheduled. No FDA approval for any medical use. The DEA's 2016 scheduling proposal remains withdrawn. Import alerts and seizures continue under FDA enforcement.
State bans (kratom illegal): Alabama, Arkansas, Indiana, Rhode Island, Vermont, Wisconsin.
Kratom Consumer Protection Acts in force: Arizona, Colorado, Georgia, Nevada, Oklahoma, Oregon, Utah, Virginia, West Virginia. These laws keep kratom legal but mandate testing, labeling, and a 21-and-over age requirement.
Local municipal bans: Sarasota County (FL), San Diego (CA), and several smaller jurisdictions. If you live or travel in these areas, check current status.
International: Banned in Australia, Denmark, Lithuania, Malaysia, Myanmar, Poland, Singapore, South Korea, Sweden, and Thailand (though Thailand re-legalized for traditional use in 2021). Legal with restrictions in Canada, Germany, the United Kingdom, and most of the European Union.
The American Kratom Association maintains a frequently updated map of state-by-state status that is the single best resource if you need a current snapshot.
Frequently Asked Questions
Is kratom a drug or a supplement?
Legally, kratom is neither a federally scheduled drug nor a dietary supplement under FDA's current position. It is sold and marketed as a botanical product. Pharmacologically, its alkaloids do behave like drugs at the receptor level, so calling it "just a supplement" is misleading.
What drug class does kratom fall under?
The closest classification is "atypical opioid agonist with stimulant properties at low doses." It does not fit cleanly into existing schedules because it acts on multiple receptor systems simultaneously and has a biphasic dose response.
Will kratom make me fail a drug test?
Not on a standard 5-panel or 10-panel test. It can fail a kratom-specific specialty panel for up to seven days after a urine sample. Tell the testing administrator if you are taking kratom and ask whether their panel includes mitragynine.
Can kratom show up as an opiate on a urine test?
True positives for opiates from pure kratom are rare because the immunoassay antibodies do not cross-react with mitragynine. False positives have been reported in a small percentage of cases on certain platforms, but confirmatory LC-MS/MS testing distinguishes the two.
Is kratom safer than opioids?
The pharmacology suggests a lower respiratory depression risk because of biased agonism at the mu-opioid receptor. Real-world fatality data show that kratom-only deaths are rare, but kratom-involved deaths in polysubstance contexts are not. "Safer" is relative and only meaningful when you control for adulterants and other substances.
Can I be addicted to kratom?
Yes. Daily use can produce physical dependence, and a meaningful minority of users meet clinical criteria for substance use disorder. Tapering protocols and harm-reduction guidance are well-documented and effective.
How long does kratom stay in your system?
The active dose wears off in three to six hours. Mitragynine itself has a half-life of around 23 hours, so the compound remains detectable on specialty assays for several days, especially in heavy users.
Final Thoughts
The most useful thing to internalize from this guide is that the word "drug" is doing different work depending on who is using it. The legal sense, the pharmacological sense, and the drug-testing sense all have separate answers, and confusing them is how myths get started.
In 2026 kratom is a legal-but-monitored botanical with real pharmacological activity, real interaction risks, and a real but mild dependence profile. It does not show up on standard drug tests and does show up on specialty ones. It is not an opioid in the traditional sense, but it touches enough of the same receptors to deserve the same caution around polysubstance use.
If you are considering kratom for the first time, start with a low dose of plain leaf powder from a vendor that publishes third-party COAs, avoid extract products until you understand how leaf affects you, and tell any prescriber you see that you are taking it. If you are already a regular user and any part of this guide raised a flag, that is worth paying attention to.
Browse our Green Vein collection for balanced everyday strains, our Red Vein collection for evening or pain-focused use, and our Premium Extracts for users who already understand leaf tolerance and want a higher-potency option.
